129 related articles for article (PubMed ID: 38261521)
21. The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment.
Yamaoka K; Kodama K; Kawaoka T; Kosaka M; Johira Y; Shirane Y; Miura R; Yano S; Murakami S; Amioka K; Naruto K; Ando Y; Kosaka Y; Uchikawa S; Uchida T; Fujino H; Nakahara T; Murakami E; Okamoto W; Yamauchi M; Miki D; Imamura M; Takahashi S; Nagao A; Chayama K; Aikata H
PLoS One; 2022; 17(1):e0262675. PubMed ID: 35041693
[TBL] [Abstract][Full Text] [Related]
22. Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma.
Su CW; Teng W; Lin PT; Jeng WJ; Chen KA; Hsieh YC; Chen WT; Ho MM; Hsieh CH; Wang CT; Chai PM; Lin CC; Lin CY; Lin SM
Cancer Med; 2023 Mar; 12(6):7077-7089. PubMed ID: 36468578
[TBL] [Abstract][Full Text] [Related]
23. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
24. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
25. Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications.
Sun X; Zhang Q; Mei J; Yang Z; Chen M; Liang T
BMC Cancer; 2022 Mar; 22(1):293. PubMed ID: 35305593
[TBL] [Abstract][Full Text] [Related]
26. Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study.
Finn RS; Kudo M; Cheng AL; Wyrwicz L; Ngan RKC; Blanc JF; Baron AD; Vogel A; Ikeda M; Piscaglia F; Han KH; Qin S; Minoshima Y; Kanekiyo M; Ren M; Dairiki R; Tamai T; Dutcus CE; Ikezawa H; Funahashi Y; Evans TRJ
Clin Cancer Res; 2021 Sep; 27(17):4848-4858. PubMed ID: 34108184
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib: A retrospective analysis.
Dong D; Shi JY; Shang X; Liu B; Xu WL; Cui GZ; Wang NY
Medicine (Baltimore); 2022 Feb; 101(5):e28680. PubMed ID: 35119010
[TBL] [Abstract][Full Text] [Related]
28. Surgical Intervention After Lenvatinib Treatment in Patients With Advanced Hepatocellular Carcinoma.
Okuno M; Hatano E; Tada M; Nishimura T; Okamoto T; Sueoka H; Iida K; Nakamura I; Iijima H; Hirono S
Anticancer Res; 2024 Apr; 44(4):1727-1737. PubMed ID: 38537993
[TBL] [Abstract][Full Text] [Related]
29. Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
Tada T; Kumada T; Hiraoka A; Michitaka K; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Nakamura S; Nouso K; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y;
Oncology; 2021; 99(8):518-527. PubMed ID: 33906189
[TBL] [Abstract][Full Text] [Related]
30. Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma.
Wu CJ; Lee PC; Hung YW; Lee CJ; Chi CT; Lee IC; Hou MC; Huang YH
Cancer Immunol Immunother; 2022 Nov; 71(11):2631-2643. PubMed ID: 35347395
[TBL] [Abstract][Full Text] [Related]
31. Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.
Kunimoto H; Shakado S; Tanaka T; Takata K; Yamauchi R; Fukuda H; Tsuchiya N; Yokoyama K; Morihara D; Takeyama Y; Hirai F; Sakisaka S
Oncology; 2020; 98(11):779-786. PubMed ID: 32877911
[TBL] [Abstract][Full Text] [Related]
32. Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma.
Camera S; Rimini M; Rossari F; Tada T; Suda G; Shimose S; Kudo M; Yoo C; Cheon J; Finkelmeier F; Lim HY; Presa J; Masi G; Bergamo F; Salani F; Marseglia M; Amadeo E; Vitiello F; Kumada T; Sakamoto N; Iwamoto H; Aoki T; Chon HJ; Himmelsbach V; Iavarone M; Cabibbo G; Montes M; Foschi FG; Vivaldi C; Lonardi S; Sho T; Niizeki T; Nishida N; Steup C; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Hiraoka A; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Imai M; Kosaka H; Naganuma A; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Persano M; Foti S; Piscaglia F; Scartozzi M; Cascinu S; Casadei-Gardini A
Target Oncol; 2024 Jan; 19(1):29-39. PubMed ID: 38252195
[TBL] [Abstract][Full Text] [Related]
33. Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative Study.
Hatanaka T; Kakizaki S; Nagashima T; Namikawa M; Ueno T; Tojima H; Takizawa D; Naganuma A; Arai H; Harimoto N; Shirabe K; Uraoka T
Oncology; 2021; 99(10):641-651. PubMed ID: 34515171
[TBL] [Abstract][Full Text] [Related]
34. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Piscaglia F; Baron A; Park JW; Han G; Jassem J; Blanc JF; Vogel A; Komov D; Evans TRJ; Lopez C; Dutcus C; Guo M; Saito K; Kraljevic S; Tamai T; Ren M; Cheng AL
Lancet; 2018 Mar; 391(10126):1163-1173. PubMed ID: 29433850
[TBL] [Abstract][Full Text] [Related]
35. Lenvatinib with or without immune checkpoint inhibitors for patients with unresectable hepatocellular carcinoma in real-world clinical practice.
Chen K; Wei W; Liu L; Deng ZJ; Li L; Liang XM; Guo PP; Qi LN; Zhang ZM; Gong WF; Huang S; Yuan WP; Ma L; Xiang BD; Li LQ; Zhong JH
Cancer Immunol Immunother; 2022 May; 71(5):1063-1074. PubMed ID: 34559308
[TBL] [Abstract][Full Text] [Related]
36. Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
Ando Y; Kawaoka T; Suehiro Y; Yamaoka K; Kosaka Y; Uchikawa S; Kodama K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Fukuhara T; Mori N; Takaki S; Tsuji K; Nonaka M; Hyogo H; Aisaka Y; Masaki K; Honda Y; Moriya T; Naeshiro N; Azakami T; Takahashi S; Imamura M; Chayama K; Aikata H
Oncology; 2020; 98(11):787-797. PubMed ID: 32882687
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study.
Hiraoka A; Kumada T; Tada T; Tani J; Kariyama K; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Aoki T; Tanaka T; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Arai T; Okubo T; Imai M; Koizumi Y; Nakamura S; Joko K; Hiasa Y; Kudo M;
Sci Rep; 2021 Aug; 11(1):16663. PubMed ID: 34404856
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China.
Wang DX; Yang X; Lin JZ; Bai Y; Long JY; Yang XB; Seery S; Zhao HT
World J Gastroenterol; 2020 Aug; 26(30):4465-4478. PubMed ID: 32874058
[TBL] [Abstract][Full Text] [Related]
39. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.
Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Cheng AL; Vogel A; Tovoli F; Ueshima K; Aikata H; López CL; Pracht M; Meng Z; Daniele B; Park JW; Palmer D; Tamai T; Saito K; Dutcus CE; Lencioni R
J Hepatol; 2023 Jan; 78(1):133-141. PubMed ID: 36341767
[TBL] [Abstract][Full Text] [Related]
40. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
Zhang W; Tong S; Hu B; Wan T; Tang H; Zhao F; Jiao T; Li J; Zhang Z; Cai J; Ye H; Wang Z; Chen S; Wang Y; Li X; Wang F; Cao J; Tian L; Zhao X; Chen M; Wang H; Cai S; Hu M; Bai Y; Lu S
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]